VEGFA and retinopathy of prematurity: In 2019, 32.6% (469 of 1440) underwent photocoagulation, 8.4% (121 of 1440) were treated with anti-VEGF monotherapy, while combined treatment (laser + anti-VEGF) was administered to 10.8% of preterm infants with ROP (156 of 1440), 33.3% of whom required an additional injection of anti-VEGF preparation after diode laser therapy (Table 1).